CORBEL Catalogue of Services

 

Why do we need a Catalogue of Services?

Currently there are 13 biological and medical sciences Research Infrastructures (RIs) in Europe, all of them working jointly together in CORBEL towards offering shared services for life-science.
All RIs offer services, i.e. researchers from academia and industry can access their facilities, technologies and expertise. Services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.

The CORBEL Catalogue of Services is the first tool to list the main services of all these RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world.

The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.
You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create your own CORBEL service pipelines, i.e. using several RIs subsequently.

Examples of service pipelines are provided here. 

>> In order to improve the catalogue, we kindly ask you to fill in a short feedback form.
     Many thanks!

What’s your need?

Please select…

EATRIS-ERIC

Website: eatris.eu

Contact person(s): Anne-Charlotte Fauvel

EATRIS supports researchers in translating their findings into novel interventions including preventive, diagnostic or therapeutic products up to clinical proof of concept. The infrastructure comprises over 90 leading research institutions in the translational field located in 12 countries across Europe. EATRIS also supports the validation and development of novel (biological) tools for precision medicine and translational research in drug development. By providing access to accredited facilities as well as market-oriented expertise, including partnering, regulatory and health-technologuy assessment, your validation needs are covered in a one-stop shop.

Services provided

Services offered by EATRIS include

  • support funding applications (Identification of partners for consortium building, assessment of the project plan's impact and innovation potential)
  • translational research facilities and expertise for development of novel biomarkers, diagnostics and therapeutics
  • molecular, functional & hybrid imaging technologies, preclinical models, samples, patient cohorts, GMP manufacturing
  • regulatory and Health Technology Assessment (HTA) expertise
  • advice on intellectual property issues and industry partnering strategy

Costs are calculated on a case by case basis depending on the service required.
For further information please contact us.

Access modes

Services performed can be offered either centrally by the coordination and support team based in Amsterdam or remotely by the EATRIS institutions.

Why to work with us

Translating novel biology insights into effective interventions or medical applications is a highly complex process. It requires significant dedicated expertise, facilities and resources. We believe in your medical innovation and we want to support you by bringing together the multi-disciplinary expertise and infrastructure required for optimising your translational trajectory. Working with EATRIS gives greater confidence in the translational feasibility of your project and its impact.

Countries involved

FR, NL, EE, CZ, SE, NO, FI, IT, ES, LV, SI, LU

ECRIN-ERIC

Website: www.ecrin.org

Contact person(s): European Correspondent in your country, Sabine Klager

ECRIN is a pan-European distributed infrastructure that links scientific partners and networks across Europe to facilitate multinational clinical research. ECRIN provides sponsors and investigators with support for the development and implementation of multinational trials.

Services provided

Services offered by ECRIN include

  • information and advice for funding applications and preparation of multinational clinical trials (methodology, operational aspects, regulatory, ethics, contracting...)
  • trial management operations (interaction with competent authorities & ethics committees, project management, monitoring, vigilance, data management)
  • clinical trial tools (outcome measures, regulatory database, site locations, risk-based monitoring)

Information and advice are free for ECRIN members. The cost of trial management services depends on the type of service requested.

Access modes

Users submit their proposal or request to ECRIN office; the access mode depends on proposal and needs.

Why to work with us

Difficulties in locating clinical trials units, fulfilling local legal, regulatory and ethical requirements, and coordinating multi-country trial management deter many researchers from attempting multinational trials. This means that most independent trials are conducted in single centres, or multiple centres within one country. ECRIN provides a pathway through Europe's fragmented health and legal systems with its pan-European infrastructure that is designed to support multinational clinical research and unlock access to patients and medical expertise.

Countries involved

FR, DE, HU, IT, NO, ES, PT
Observer: CZ, CH

EU-OPENSCREEN

Website: www.eu-openscreen.eu

Contact person(s): Dr. Katja Herzog, Dr. Bahne Stechmann

EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists. EU-OPENSCREEN offers to researchers from academic institutions, SMEs and industrial organisations open access to its shared resources.

EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences.

Services provided

Services provided by EU-OPENSCREEN include

  • high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits
  • access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)
  • assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors 
  • chemical optimization and profiling of preliminary ‘hits’
  • bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.
  • provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.
  • training and education

A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k €, strongly depending on the number of screened substances and the maturity/ complexity of the assay.
A compound replenishment fee structure applies to all projects using the EU-OPENSCREEN compound collection and users from countries which are members of the EU-OPENSCREEN ERIC will receive a discount on this cost.
For further information please contact us.

Access modes

Users are requested to submit project proposal to the EU-OPENSCREEN office. Depending on the project requirements, the RI can be assessed remotely or on-site.

Why to work with us

The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through grant application processes and beyond for funding involving screening projects.

Countries involved

CZ, DK, FI, DE, GR, NL, NO, PL, ES, AT, FR, HU, IL, PT, RO, SE

Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!

This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654248.

Days
Hours
Minutes
Seconds

left to apply to the final Open Call submission round –
don’t miss this last chance! »

Open Call